Antibody-drug conjugates (ADCs) have gone through several waves of enthusiasm since being first tested in animal models in the 1960’s. The first clinical trials with ADCs were conducted in the 1980’s, and an ADC was first approved in 2000 (Mylotarg, see below). Mylotarg, however, was famously withdrawn from the market Read more…
Recently our non-profit partner, California Life Sciences, completed nominations for the 2021 Pantheon Award for Scientific Advancement. We’re glad to see several drug hunters and drug discovery companies across the award categories, and we hope you’ll help get some industry drug hunters deserved recognition for their achievements by voting here! Read more…
The August edition of Small Molecules of the Month, features a recently approved, dibasic oral kallikrein inhibitor, a spirocyclobutene-containing FXR agonist, a NaV1.6 clinical candidate, a remarkably long acting RIPK2 PROTAC, and several other interesting clinical candidates. Thanks to reviewers Joachim Rudolph, Kim Huard, Jake Schwarz, Julien Lefranc, and Chris Read more…
By Christian Kuttruff and Julien Lefranc The first disclosures of new drug candidates are always the highlight of medicinal chemistry conferences. Six novel drug candidates were recently disclosed by European companies at the European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry (EFMC-ISMC) Conference in Basel, including a KRAS Read more…
Recently, our team at Drug Hunter compiled the lead programs and mechanisms of small molecule and large molecule biotechs that IPO’d in 2020. We asked featured reviewers from our community what stood out to them about the science of this group of companies, and here are some highlights that emerged Read more…
Thanks to our featured reviewers for their feedback, with special thanks to neuroscience reviewer Jake Schwarz for feedback and commentary on an unusual 5 neuroscience molecules this month. July’s edition of Small Molecules of the Month, features a selective monovalent estrogen receptor degrader in Ph. III, a remarkable 4(!) neurology Read more…